Ssatuximab (Sarclisa, Sanofi) is used in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma.In April, the FDA approved isatuximab (Sarclisa, Sanofi) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple ...
Compared to females, males have lower levels of cytochrome P450 3A4 (CYP3A4), for which erythromycin is both a substrate and inhibitor. Use of CYP3A4-inhibiting drugs such as erythromycin in men may thus result in even lower levels of CYP3A4 and, consequently, higher levels of CYP3A4-...
FDA confirms approval of Karyopharm treatment for refractory multiple myeloma As a result of the reports, the FDA has updated the drug label prescribing information and the patient Medication Guide to reflect these risks, and added the risk of stroke to the medication's existing boxed warning. Str...
Multiple myeloma is a neoplastic process characterized by the proliferation of lymphoplasmacytic cells in the bone marrow.1-6The condition is responsible for the production of immunoglobulin antibodies which lead to excessively high levels.3The disease is characterized by generalized fatigue, weight loss...
(40%) cancer, and multiple myeloma (95%), to reduce the risk of skeletal-related events (SREs), chemotherapy-induced bone loss and to treat hypercalcaemia. Their effectiveness in reducing SREs has led to their integration into guideline based cancer care [1,2,5,6]. Practising oncologists...
Bisphosphonates are drugs used in the treatment of lytic bone metastases, multiple myeloma, hypercalcemia of malignant origin, osteoporosis, an... K Popovic,M Kocar - 《Radiology & Oncology》 被引量: 59发表: 2010年 Current perspectives on bisphosphonate treatment in Paget's disease of bone. two...
(40%) cancer, and multiple myeloma (95%), to reduce the risk of skeletal-related events (SREs), chemotherapy-induced bone loss and to treat hypercalcaemia. Their effectiveness in reducing SREs has led to their integration into guideline based cancer care [1,2,5,6]. Practising oncologists...
and systematic and targeted approaches are still lacking. Maxillofacial surgeons focus on the etiology of osteonecrosis in the mandible and maxilla as well as the appropriate oral interventions for high-risk patients. Adequate nursing care and pharmacotherapy management are also crucial. This review provi...
AURIGA Results Support Addition of Daratumumab in Maintenance Setting for Myeloma Latest CARTITUDE-4 Data Highlight the Benefits of Cilta-Cel in Multiple Myeloma Expert Reviews Findings From the AURIGA Study in Myeloma Expert: Pharmacists Are Essential When Monitoring Patients On T Cell-Directed Therapie...
Bisphosphonates are the most widely prescribed drugs for the treatment of osteoporosis, and are also used in malignant bone metastases, multiple myeloma, a... KK Min,R Yumie,K Yong-Dae,... - 《J Bone Metab》 被引量: 41发表: 2015年 Clinical study evaluating the effect of bevacizumab on ...